Kiniksa Pharmaceuticals International, plc

For the period ended Dec 31, 2025. Filed Feb 24, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 24, 2026

KNSA$95.02-3.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)


· · Years Ended
· · December 31,
· · 2025 · · 2024 · · 2023
Cash flows from operating activities: · · · · · · · ·
Net income (loss)	$59,005	$(43,193)	$14,084
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization expense	1,554	1,695	2,341
Share-based compensation expense	37,003	30,693	27,149
Non-cash lease expense	3,666	3,136	3,054
Net amortization (accretion) of discounts on short-term investments	(916)	441	(1,068)
Net (gain) loss on disposal of property and equipment	(120)	(24)	179
Deferred income taxes	13,002	8,132	(33,788)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(22,481)	(2,710)	(7,067)
Accounts receivable, net	26,130	(20,458)	(8,606)
Inventory	(28,531)	4,758	(9,523)
Contract asset	—	—	7,656
Other long-term assets	(1,210)	(9,735)	4,584
Accounts payable	142	(6,306)	347
Accrued expenses, accrued collaboration expenses and other current liabilities	37,497	43,729	16,940
Operating lease liabilities	(3,455)	(3,984)	(3,261)
Deferred revenue	—	19,550	261
Other long-term liabilities	16,699	(35)	19
Net cash provided by operating activities	137,985	25,689	13,301
Cash flows from investing activities:
Proceeds from sale of property and equipment	—	25	—
Purchases of property and equipment	(1,568)	(277)	(130)
Purchases of short-term investments	(386,915)	(202,014)	(204,933)
Proceeds from the maturities of short-term investments	199,490	239,938	175,506
Net cash provided by (used in) investing activities	(188,993)	37,672	(29,557)
Cash flows from financing activities:
Proceeds from issuance of Class A ordinary shares under incentive award plans and employee share purchase plan	40,753	17,250	3,701
Payments in connection with ordinary stock tendered for employee tax obligations	(7,730)	(4,984)	(2,206)
Net cash provided by financing activities	33,023	12,266	1,495
Net increase (decrease) in cash and cash equivalents	(17,985)	75,627	(14,761)
Cash and cash equivalents at beginning of period	183,581	107,954	122,715
Cash and cash equivalents at end of period	$165,596	$183,581	$107,954

Supplemental information:
Cash paid for income taxes, net	$3,012	$2,003	$5,605

Supplemental disclosure of non-cash investing and financing activities:
Change in right-of-use asset as a result of new, modified, and terminated leases	$3,097	$1,581	$9,600
Additions to property and equipment included in accrued expenses and other liabilities	$83	$153	$54

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.